	Application No.	Applicant(s)
Notice of Allowability	09/811,870	COLE ET AL.
	Examiner	Art Unit
	David J. Steadman	1656
The MAILING DATE of this communication apperature All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOT OF THE OFFICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOT AND THE OFFICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOT OF THE OFFICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIOT OF THE OFFICE	(OR REMAINS) CLOSED in this ap or other appropriate communication IGHTS. This application is subject to and MPEP 1308.	orrespondence address plication. If not included n will be mailed in due course. THIS
1. A This communication is responsive to the amendment filed	<u>on 11/3/2005</u> .	
2. X The allowed claim(s) is/are <u>15</u> .		
<ul> <li>3. Acknowledgment is made of a claim for foreign priority ur</li> <li>a) All b) Some* c) None of the:</li> <li>1. Certified copies of the priority documents have</li> <li>2. Certified copies of the priority documents have</li> </ul>	e been received.	
3. Copies of the certified copies of the priority documents have been received in this national stage application from the		
International Bureau (PCT Rule 17.2(a)).		
* Certified copies not received:		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.  THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
4. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give		
5. CORRECTED DRAWINGS ( as "replacement sheets") mus	st be submitted.	
(a) ☐ including changes required by the Notice of Draftspers	son's Patent Drawing Review ( PTO-	948) attached
1)  hereto or 2)  to Paper No./Mail Date		
(b) ☐ including changes required by the attached Examiner's Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).		
6. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
·		
Attachment(s)	e 🗆 Nation (1.6)	0-AA A
<ol> <li>Notice of References Cited (PTO-892)</li> <li>Notice of Draftperson's Patent Drawing Review (PTO-948)</li> </ol>		Patent Application (PTO-152)
	Paper No./Mail Da	
<ol> <li>Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date</li> </ol>	08), 7. ⊠ Examiner's Amendi	ment/Comment
Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. Examiner's Stateme	ent of Reasons for Allowance
<del></del>	9.	

#### **DETAILED ACTION**

# Status of the Application

- [1] Claim 15 is pending in the application.
- [2] Applicant's amendment to the claims, filed on 11/3/2005, is acknowledged. This listing of the claims replaces all prior versions and listings of the claims.

# Examiner's Amendment to the Specification

[3] An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Sarah Kagan on 11/14/2005.

[4] After the second sentence in ¶ [17] of the specification, *i.e.*, the sentence that reads: "Compound 1 was synthesized...PKA inhibitor", please insert "R<sub>1</sub> of Compound 1 is SEQ ID NO:6."

#### Examiner's Amendment to the Claim

[5] An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Sarah Kagan on 11/14/2005.

[6] Insert a period, i.e., ".", at the end of claim 15.

### Examiner's Comment

[7] It is noted that R<sub>1</sub> of claim 15 is defined as "AcNH-..." It is well-known in the art that "Ac" at the N-terminus of a peptide denotes an acetyl group. See, *e.g.*, Rosse et al., *Helvetica Chimica Acta* 80 :653-670 (cited in the IDS filed on 3/20/2002), particularly scheme 1 at p. 656. In a telephone conversation with Ms. Sarah Kagan on 11/14/2005, it was clarified that "Ac" of R<sub>1</sub> does indeed represent an acetyl group. Thus, "AcNH-" indicates the presence of an acetyl group attached to the amino group of the N-terminal Lys residue of R<sub>1</sub>.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David J. Steadman whose telephone number is 571-272-0942. The examiner can normally be reached on Monday to Thursday, 6:30 am to 5:00 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Kathleen Kerr can be reached on 571-272-0931. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

David J. Steadman, Ph.D.

**Primary Examiner** 

Art Unit 1656